VIGNETTI, Marco
 Distribuzione geografica
Continente #
NA - Nord America 237
EU - Europa 121
AS - Asia 62
SA - Sud America 6
OC - Oceania 4
AF - Africa 1
Totale 431
Nazione #
US - Stati Uniti d'America 231
FR - Francia 43
IT - Italia 43
CN - Cina 41
DE - Germania 11
IN - India 8
CA - Canada 6
GB - Regno Unito 5
AU - Australia 4
BG - Bulgaria 4
JP - Giappone 4
HU - Ungheria 3
TR - Turchia 3
BR - Brasile 2
CL - Cile 2
FI - Finlandia 2
HK - Hong Kong 2
NL - Olanda 2
PE - Perù 2
RU - Federazione Russa 2
AT - Austria 1
BE - Belgio 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
ID - Indonesia 1
KR - Corea 1
KW - Kuwait 1
SG - Singapore 1
UA - Ucraina 1
Totale 431
Città #
Fairfield 29
Rome 20
Buffalo 19
Seattle 18
Santa Cruz 14
Ashburn 12
Paris 12
Houston 11
Cambridge 8
Chicago 7
Los Angeles 6
Boardman 5
Hangzhou 5
Woodbridge 5
Beijing 4
Shanghai 4
Sofia 4
Wilmington 4
Cedar Knolls 3
Clearwater 3
Des Moines 3
Göttingen 3
Istanbul 3
New York 3
Phoenix 3
San Diego 3
Ann Arbor 2
Budapest 2
Cleveland 2
Henderson 2
Kowloon 2
Las Vegas 2
Lima 2
Lodi 2
Mumbai 2
Nagae 2
Ottawa 2
Riva 2
Rocca di Papa 2
San Jose 2
Santa Clara 2
Soleto 2
São Paulo 2
Toronto 2
Wuhan 2
Youngstown 2
Alexandria 1
Amsterdam 1
Andover 1
Arzignano 1
Barcelona 1
Barking 1
Bhavnagar 1
Bremen 1
Brisbane 1
Brockport 1
Brooklyn 1
Bucheon-si 1
Changsha 1
Chapel Hill 1
Chennai 1
Cheyenne 1
Council Bluffs 1
Crugers 1
Essen 1
Fleming Island 1
Frankfurt am Main 1
Gaithersburg 1
Geel 1
Grenoble 1
Guangzhou 1
Gurgaon 1
Haidian 1
Hamilton 1
Helsinki 1
Heraklion 1
Hyderabad 1
Jackson Heights 1
Jakarta 1
Kuwait 1
Ladispoli 1
Lanzhou 1
Lappeenranta 1
Lido di Ostia 1
London 1
Martonvasar 1
Milan 1
Milwaukee 1
Montecchio Maggiore 1
Montreal 1
Monza 1
Nagoya 1
Neijiang 1
New Kensington 1
New Orleans 1
Newport Beach 1
Omaha 1
Perugia 1
Piacenza 1
Pontinia 1
Totale 305
Nome #
null, file e383531a-c0f9-15e8-e053-a505fe0a3de9 90
Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults, file e383532e-7262-15e8-e053-a505fe0a3de9 73
Francesco Lo Coco, a distinguished hematologist and a friend, file e3835323-e6e8-15e8-e053-a505fe0a3de9 68
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2), file e3835326-a082-15e8-e053-a505fe0a3de9 61
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial, file e383532e-7042-15e8-e053-a505fe0a3de9 33
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial, file 9bb05ffd-83cc-430d-82a1-81a462609e51 19
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications., file e383531a-9c6f-15e8-e053-a505fe0a3de9 18
Lymphadenopathies before and during the pandemic COVID-19: increasing incidence of metastases from solid tumors, file a22197bc-b205-4ebc-8c46-c227aa3317b0 16
The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials, file ff2154a0-495a-44a5-b8f2-85f75054a796 16
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients. Final results of the GIMEMA LAL1509 protocol, file e383532e-a839-15e8-e053-a505fe0a3de9 13
null, file 645b479f-f5d6-4bd9-9ed2-330beda705c4 11
P523: The comparison of VFLAI, FLAI and 3 + 7 regimens by multilevel propensity score weighting highlights the benefit of the addition of venetoclax in no low risk aml treated in Gimema trials real world, file 8cedfab9-5b5e-4f5a-ac44-68017d4f6192 7
P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE, file 65f23933-9470-40d1-8143-b275f12570a8 6
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia, file d1fdacb6-5b1b-42eb-b7bd-173041a08828 2
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications, file e3835329-89e4-15e8-e053-a505fe0a3de9 2
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity, file e383532d-1d99-15e8-e053-a505fe0a3de9 2
GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children., file e3835311-a457-15e8-e053-a505fe0a3de9 1
Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study, file e3835311-ee88-15e8-e053-a505fe0a3de9 1
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders, file e3835319-ba8b-15e8-e053-a505fe0a3de9 1
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes, file e3835323-e6eb-15e8-e053-a505fe0a3de9 1
Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996, file e383532e-6307-15e8-e053-a505fe0a3de9 1
Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis, file ec95af8c-91db-4d65-8fe3-36ac96a05e2f 1
Totale 443
Categoria #
all - tutte 1.213
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.213


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201924 0 0 0 0 0 0 0 0 0 9 7 8
2019/202053 3 4 2 2 3 3 9 9 8 3 5 2
2020/202141 3 6 3 3 1 3 3 3 8 1 3 4
2021/202283 6 2 5 1 7 1 1 4 6 11 23 16
2022/2023102 6 7 16 12 8 10 8 6 2 5 13 9
2023/2024133 6 20 6 9 24 22 24 15 5 2 0 0
Totale 443